Claims for Patent: 10,407,480

Summary for Patent: 10,407,480

Title:	Targeted modified TNF family members
Abstract:	The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.
Inventor(s):	Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
Assignee:	Universiteit Gent , Vlaams Instituut voor Biotechnologie VIB , Centre National de la Recherche Scientifique CNRS , Centre Hospitalier Universitaire de Montpellier , Universite de Montpellier
Application Number:	US16/020,469

Details for Patent 10,407,480

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Rare Disease Therapeutics, Inc. (rdt)	ANAVIP	crotalidae immune f(ab')2 (equine)	For Injection	125488	May 06, 2015		2038-06-27

International Patent Family for US Patent 10,407,480

Country	Patent Number	Estimated Expiration
Australia	2014291961
Brazil	112016001114
Canada	2918363
China	105492017
Denmark	3021865
European Patent Office	3021865